Fertility After Transvaginal Surgery or Uterine Artery Embolization Combined With Uterine Curettage in Patients With Cesarean Scar Pregnancy

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02933190

Enrollment

Registered

2016-10-14

Start date

2016-11-30

Completion date

2019-12-31

Last updated

2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnetic Resonance Imaging, Menstruation, Ovarian Function

Brief summary

To investigate the fertility in patients after treatment by transvaginal surgery or uterine artery embolization combined with uterine curettage

Interventions

PROCEDUREtransvaginal surgery；UAE and D&C

For cesarean scar pregnancy treatment

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* increased levels of serum β-hCG and ultrasonography findings. The criteria for diagnosis by ultrasonography was the presence of the following: (1) an empty uterine cavity and endocervical canal; (2) detection of the placenta and/or a gestational sac embedded in the hysterectomy scar; (3) the presence of the gestation sac with or without a fetal pole and with or without fetal cardiac activity (depending on the gestational age) in the anterior part of the uterine isthmus; and (4) a thin (1-3 mm) or absent myometrial layer between the gestational sac and the bladder(24). All patients had taken Magnetic Resonance Imaging (MRI) to clarify the diagnosis . Pregnancy tissues were identified by histopathology examinations of the surgical tissues.

Exclusion criteria

* All enrolled patients had no contraindications for transvaginal surgery or UAE, including renal failure, active pelvic infection, clotting disorders, or known allergy to the contrast material.

Design outcomes

Primary

Measure	Time frame
Duration of menstruation by questionnaire (days)	six months after treatment
Endocrine level by blood examination (FSH in IU/L)	six months after treatment
Volume of menstruation by questionnaire (in pictorial blood loss score)	six months after treatment

Secondary

Measure	Time frame
The length of the CSD by MRI (millimeter)	six months after treatment
The width of the CSD by MRI (millimeter)	six months after treatment
The depth of the CSD by MRI (millimeter)	six months after treatment

Countries

China

Contacts

Primary ContactXipeng Wang

xipengwang@hotmail.com0086-13817806602

Backup ContactHuihui Chen

huihui78505@hotmail.com0086-13916278505

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026